Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “AstraZeneca”
- CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)Active Not Recruiting
Sponsor: University of Birmingham
Oropharyngeal Cancer
Ireland, United Kingdom
Sponsor: AstraZeneca
Heathy Participants
United States
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, Australia, Brazil, Canada, China +14 more
Sponsor: Australasian Gastro-Intestinal Trials Group
Cholangiocarcinoma
Australia
- BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREANot Yet Recruiting
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
- Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive Not Recruiting
Sponsor: AstraZeneca
Hormone-Sensitive Prostate Cancer
United States, Argentina, Australia, Austria, Belgium +27 more
Sponsor: AstraZeneca
Breast Cancer
United States, Argentina, Belgium, Brazil, Canada +15 more
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States
Sponsor: M.D. Anderson Cancer Center
Adenoid Cystic Carcinoma
United States
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive Not Recruiting
Sponsor: Massachusetts General Hospital
Hepatocellular Carcinoma · Biliary Tract Cancer
United States
Sponsor: Maximilian Diehn
Non Small Cell Lung Cancer · NSCLC, Stage III · Nsclc
United States
Sponsor: AstraZeneca
Metastatic Prostate Cancer
Brazil
- Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)Active Not Recruiting
Sponsor: AstraZeneca
Non-small Cell Lung Cancer NSCLC
United States, Belgium, Hungary, India, Japan +7 more
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
Russia
Sponsor: iOMEDICO AG
CLL
Germany
- Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerActive Not Recruiting
Sponsor: AstraZeneca
Locally Advanced (Inoperable) or Metastatic Breast Cancer
United States, Argentina, Australia, Belgium, Canada +14 more
- Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active Not Recruiting
Sponsor: University Hospital Southampton NHS Foundation Trust
Diffuse Large B Cell Lymphoma
United Kingdom
Sponsor: Université de Sherbrooke
Asthma · Inflammation · Asthma in Children
Canada
- Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active Not Recruiting
Sponsor: AstraZeneca
Advanced Hepatocellular Carcinoma
United States, France, Germany, Hong Kong, Italy +5 more
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive Not Recruiting
Sponsor: Dana-Farber Cancer Institute
Non-Small Cell Lung Cancer
United States
- Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With PolyangiitisActive Not Recruiting
Sponsor: Imperial College London
EGPA - Eosinophilic Granulomatosis With Polyangiitis
United Kingdom
- Osimertinib In EGFR Mutant Lung CancerActive Not Recruiting
Sponsor: Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung
United States
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerRecruiting
Sponsor: Hirva Mamdani
Small Cell Lung Cancer · SCLC · Extensive Stage Small Cell Lung Cancer · Limited Stage Small-Cell Lung Cancer
United States
Sponsor: University of Birmingham
Non-Small Cell Lung Cancer · Carcinoma, Squamous Cell · Adenocarcinoma
United Kingdom
Sponsor: OHSU Knight Cancer Institute
Advanced Breast Carcinoma · Advanced Malignant Solid Neoplasm · Advanced Ovarian Carcinoma · Advanced Pancreatic Carcinoma
United States